Adjuvant Trastuzumab in HER2-Positive Breast Cancer-Reference-Cited by-同舟云学术

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Published:2011-10-06 Issue:14 Volume:365 Page:1273-1283
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Slamon Dennis,Eiermann Wolfgang,Robert Nicholas,Pienkowski Tadeusz,Martin Miguel,Press Michael,Mackey John,Glaspy John,Chan Arlene,Pawlicki Marek,Pinter Tamas,Valero Vicente,Liu Mei-Ching,Sauter Guido,von Minckwitz Gunter,Visco Frances,Bee Valerie,Buyse Marc,Bendahmane Belguendouz,Tabah-Fisch Isabelle,Lindsay Mary-Ann,Riva Alessandro,Crown John

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910383

Cited by 2240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo;Translational Oncology;2024-11

2. Human Blood Serum Antagonizes Effects of EGFR/HER2-Targeted Drug Lapatinib on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Биохимия;2024-09-14

3. Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data;European Journal of Cancer;2024-09

4. HER-2 Receptor and αvβ3 Integrin Dual-Ligand Surface-Functionalized Liposome for Metastatic Breast Cancer Therapy;Pharmaceutics;2024-08-27

5. miR-424-5p suppresses the proliferation and immigration of oral squamous cell carcinoma via down-regulation of KDR;Aging;2024-08-26